← Russell 3000 cross-section

SGHT Sight Sciences, Inc.

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$466m
Revenue TTM
$83m
Net income TTM
$-30m
Free cash flow
$-23m
Composite score
40.8
Sector rank
#2431

Valuation

P / E
EV / EBITDA
EV / sales
5.1
FCF yield
-5.01%
Earnings yield vs 10-yr
-11.13pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-35.7%
EBITDA margin
-32.9%
ROE
-56.3%
ROIC
-200.3%
Revenue growth
9.3%

Insider activity, last 90 days

Net open-market
$-0.38m
Buyers
1
Sellers
6

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

Each product is primarily sold through a highly involved direct sales model that offers intensive education, training and customer service. To date, the revenue from our Interventional Glaucoma segment has accounted for the vast majority of our total revenue, substantially all of which was generated from sales within the U.S. No single customer accounted for 10% or more of our revenue for the three and six months ended June 30, 2026 and 2025. The growth of our revenue is primarily driven by the demand for elective surgery and treatment utilizing our products in the United States and Europe, product reimbursement rates and coverage criteria, and competition. …Sight Sciences, Inc., 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →